Cesano A, Visonneau S, Rovera G, Santoli D
Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Anticancer Res. 1997 May-Jun;17(3C):1887-92.
The single and combined antitumor effects of adriamycin and a major histocompatibility complex non-restricted human cytotoxic T cell line (TALL-104) were evaluated in severe combined immunodeficient (SCID) mice engrafted subcutaneously with a biopsy sample from a patient with a highly metastatic gastric carcinoma. Chemotherapy was initiated 3 weeks after tumor implantation, when local growth was advanced, and consisted of 2 weekly injections of adriamycin. gamma-irradiated (40 Gy) TALL-104 cells were administered daily for 2 weeks, starting 1 day after the end of chemotherapy. While TALL-104 cells or adriamycin alone did not inhibit tumor growth, synergistic antitumor effects were seen with the two treatments combined. These findings suggest that chemotherapy in conjunction with cell therapy are effective in overcoming tumor resistance to single therapeutic agents through mechanisms independent from the host immune system.
在严重联合免疫缺陷（SCID）小鼠皮下植入一位高转移性胃癌患者的活检样本后，评估了阿霉素和一种主要组织相容性复合体非限制性人类细胞毒性T细胞系（TALL-104）的单一及联合抗肿瘤作用。肿瘤植入3周后，当局部生长进展时开始化疗，化疗方案为每周注射2次阿霉素。在化疗结束后1天开始，每天给予经γ射线照射（40 Gy）的TALL-104细胞，持续2周。虽然单独使用TALL-104细胞或阿霉素均未抑制肿瘤生长，但两种治疗联合使用时观察到了协同抗肿瘤作用。这些发现表明，化疗与细胞治疗相结合可通过独立于宿主免疫系统的机制有效克服肿瘤对单一治疗药物的耐药性。
